L-DOPA therapy interferes with urine catecholamine analysis in children with suspected neuroblastoma: a case series. (September 2017)

• Record Type: Journal Article
• Authors: Kelly, Alison U; Srivastava, Rajeev; Dow, Ellie; Davidson, D Fraser
• Is Part Of: Annals of clinical biochemistry. Volume 54:Number 5(2017:Sep.)
• Page Start: 616
• Page End: 621
• Publication Date: 2017-09
• Subjects: Neuroblastoma -- L-DOPA -- catecholamines -- metanephrines -- urine; Clinical chemistry -- Periodicals; Clinical biochemistry -- Periodicals; 616.075
• DOI: 10.1177/0004563216686993
• Languages: English
• ISSNs: 0004-5632

Abstract

Neuroblastoma is the most common solid extracranial malignancy diagnosed in childhood. Clinical presentation is variable, and metastatic disease is common at diagnosis. Analyses of urinary catecholamines and their metabolites are commonly requested as a first-line investigation when clinical suspicion exists. Levodopa (L-Dopa) therapy is utilized as a treatment for a number of disorders in childhood, including Dopa-responsive dystonia. Neuroblastoma may mimic some of the clinical features of this disorder. L-Dopa can interfere with analysis of urinary catecholamines and their metabolites and complicate the interpretation of results. We present the cases of three children who were prescribed L-dopa at the time of analysis of urinary catecholamines and metabolites as a screen for neuroblastoma, but who did not have the disease. Comparison of their results with those from cases with true neuroblastoma reveal that it is impossible to reliably distinguish true neuroblastoma from L-Dopa therapy using these tests. We recommend that patients should be off L-dopa therapy, if possible when these tests are performed. These cases illustrate the importance of providing clinical details and drug history to the laboratory in order to avoid diagnostic confusion.